Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
1 in 6 people worldwide experience infertility and up to 50% of the time there is a contributing male factor.1,2,3 Stigma,…
-
-
First Real-World Outcomes Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at DDW 2024
First real-world outcomes analysis evaluated efficacy of REBYOTA in patients with recurrent C. diff infection Ad-hoc analysis evaluated efficacy and…
-
Ferring Announces U.S. FDA Acceptance of Biologics License Application Submission for SI-6603, an Investigational Therapy in Lumbar Disc Herniation
SI-6603 is an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation Lumbar disc herniation can…
-
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3…
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal…
-
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies…
-
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a…
-
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts
Results of a Phase 3 study show durable complete response in evaluation of high-grade recurrence-free survival, cystectomy-free survival, and overall…
-
Ferring Position on Alabama Supreme Court Ruling in LePage v Mobile Infirmary Clinic
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility…
-
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium…